IRVINE, CA, and HERSTAL, BELGIUM – August 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the second quarter and six-month period ended June 30, 2024, after market close on Wednesday, August 21, 2024.
| Title: | MDxHealth Presents Second Quarter and First Half 2024 Financial Results and Corporate Update Conference Call and Webcast |
| Speakers: | Michael K. McGarrity, Chief Executive Officer Ron Kalfus, Chief Financial Officer |
| Date: | August 21, 2024 |
| Time: | 4:30pm ET/ 22:30 CET |
| Conference Call Dial-in Details: | United States: 1-877-407-9716 Belgium: 0800 73 566 The Netherlands: 0800 022 3580 United Kingdom: 0 800 756 3429 |
| Conference ID: | 13747618 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1679031&tp_key=41436200eb |
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.
About MDxHealth
Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands. For more information, visit mdxhealth.com and follow us on social media at: www.twitter.com/mdxhealth, www.facebook.com/mdxhealth and www.linkedin.com/company/mdxhealth.
| MDxHealth This email address is being protected from spambots. You need JavaScript enabled to view it. | |
| LifeSci Advisors (IR & PR) US: +1 949 271 9223 This email address is being protected from spambots. You need JavaScript enabled to view it. |
NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype DX trademark, and all other trademarks and service marks, are the property of their respective owners.
| Last Trade: | US$4.04 |
| Daily Change: | -0.26 -6.05 |
| Daily Volume: | 126,388 |
| Market Cap: | US$199.980M |
July 03, 2025 May 14, 2025 February 26, 2025 February 12, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
